mfn-cus-other-press-releases

Nanologica Receives Order for Silica for Preparative Chromatography from US Customer

3 October, 2022

Nanologica AB (publ) has received an order for the company's silica for preparative chromatography to a value of approximately TSEK 230. The order comes from a customer in the North American market. During 2022, Nanologica has completed the up-scaling to large-scale production of the company’s commercial silica for preparative chromatography, NLAB Saga®. This order is a direct consequence of the company now being able to deliver the volumes of silica required for customers to be

Nanologica Expands Management Team for Increased Focus on Chromatography

10 August, 2022

Nanologica AB (publ) has expanded its management team with Katarina Alenäs, SVP Chromatography, as part of intensifying the company’s efforts within preparative chromatography. Katarina Alenäs took up her position as SVP Chromatograhy at Nanologica in the beginning of March, and most recently came from a role as Business Team Manager Sweden and Finland, Country General Manager Sweden and chairman of the board of Agilent Technologies Sweden AB. Katarina has a solid background and a strong

Proposal for New Stock Option Program Withdrawn

31 May, 2022

The board of directors of Nanologica AB (publ) has decided to withdraw the proposal for a new stock option program for management and employees that was presented in the notice to Nanologica's Annual General Meeting on June 2, 2022. The board of directors has decided to withdraw the proposal to await the outcome of the stock option programs that expire on July 1 this year. Depending on the outcome, a new stock option program may

Nanologica takes out loan of MSEK 20 within agreed credit facility

25 April, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company's temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, MSEK 20 remains of the credit facility. For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

Nanologica Expands Launch Road Show after Good Reception

12 April, 2022

After a successful first activity of the global launch of the company's silica for preparative chromatography, NLAB Saga®, Nanologica expands the road show with participation at additional chromatography conferences. The launch of Nanologica’s silica for preparative chromatography started at the Purify'22 Chromatography Purification Conclave on April 7 in Hyderabad, India, where the products received a very good reception. In light of this, Nanologica has expanded its road show with additional conferences for chromatography. The company

Nanologica to Attend Conferences in Preparative Chromatography

31 March, 2022

Nanologica will be attending several chromatography conferences during the spring in connection to the launch of the company’s silica for preparative chromatography, NLAB Saga®. The road show starts on April 7 at Purify’22 Chromatography Purification Conclave in Hyderabad, India, where Nanologica’s CEO Andreas Bhagwani will give the inaugural address on Pharmaceutical Megatrends and the Fundamental Impact of Chromatography, and where Nanologica’s SVP Chromatography Katarina Alenäs will give a talk on New Generation Silica for Peptide

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.